<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642639</url>
  </required_header>
  <id_info>
    <org_study_id>CNV_2017_01</org_study_id>
    <nct_id>NCT03642639</nct_id>
  </id_info>
  <brief_title>A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms</brief_title>
  <acronym>STERLING</acronym>
  <official_title>A Prospective, Multi-center, Single Arm Study to Obtain &quot;Real World&quot; Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils Including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerenovus, Part of DePuy Synthes Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerenovus, Part of DePuy Synthes Products, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and&#xD;
      GALAXY coils&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A registry to collect real world data on the use of Cerenovus coils. The study will be a&#xD;
      post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and&#xD;
      GALAXY coils&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occlusion Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Occlusion rate at 12 Months post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Packing Density</measure>
    <time_frame>From enrollment to end of treatment at 12 months</time_frame>
    <description>Packing density will be evaluated based on aneurysm volume and the coils used during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Complete occlusion rate</measure>
    <time_frame>12 month</time_frame>
    <description>Complete occlusion rate at 12 month follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Recanalization Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Recanalization Rate: Any worsening of occlusion grading at 12 Month follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Device related serious adverse events</measure>
    <time_frame>12 Months</time_frame>
    <description>Any device related serious adverse events will be reported through 12 month follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Retreatment Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Aneurysm re-treatment rates will be tracked and recorded during the 12 month follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Modified Rankin Score</measure>
    <time_frame>12 Months</time_frame>
    <description>Modified Rankin Score (Scale from 0-6) at 12 Months. 0 - No symptoms.&#xD;
- No significant disability. Able to carry out all usual activities, despite some symptoms.&#xD;
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.&#xD;
- Moderate disability. Requires some help, but able to walk unassisted.&#xD;
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.&#xD;
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.&#xD;
- Dead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7. Length of hospital stay</measure>
    <time_frame>From enrollment to 12 Months</time_frame>
    <description>Hospital stay length will be recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Aneurysms</condition>
  <arm_group>
    <arm_group_label>Coils</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MICRUSFRAME and GALAXY coils</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MICRUSFRAME and GALAXY coils</intervention_name>
    <description>MICRUSFRAME and GALAXY Coils</description>
    <arm_group_label>Coils</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is between 21 and 80 years of age&#xD;
&#xD;
          2. Patient has an intracranial saccular aneurysm, ruptured or unruptured, suitable for&#xD;
             embolization with coils&#xD;
&#xD;
          3. Patient is able and willing to comply with protocol and follow-up requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-planned staged procedure on unruptured aneurysm&#xD;
&#xD;
          2. More than one aneurysm requiring treatment during the course of study&#xD;
&#xD;
          3. Fusiform aneurysm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reade De Leacy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osama Zaidat</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Health St. Vincent Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lillian Ma</last_name>
    <phone>9494668021</phone>
    <email>lma46@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reade De Leacy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Osama Zaidat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Francois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

